Who
Margaret Smith Bell
Director
Company insider
Files Form 4 as: Director, Tonix Pharmaceuticals Holding.
In numbers
- Trades disclosed
- 12
- Buys
- 1
- Sells
- 0
- Bought
- $5,014
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 12 Jun 2018
- Last trade
- 12 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 14 May 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Feb 2025filed 28 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $01 at $0.15 | filing |
| 23 May 2024filed 24 May 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,621 at $0.00 | filing |
| 8 May 2023filed 10 May 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 9 May 2022filed 11 May 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,131,500 at $0.00 | filing |
| 10 May 2021filed 12 May 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,882 at $0.00 | filing |
| 20 Aug 2020filed 24 Aug 2020 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $5,0145,391 at $0.93 | filing |
| 4 May 2020filed 6 May 2020 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 6 May 2019filed 8 May 2019 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 12 Jun 2018filed 13 Jun 2018 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, MontanaTNXP · matr.net · 12 Oct 2026
0 headlines in the last 90 days name Margaret Smith Bell; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.